Company intelligence / Profile preview

Carag

Ownership: Private
Development stage: Commercial

Overview

Carag has developed the Carag Bioresorbable Septal Occluder™, which has been used in first-in-child clinical experience for transcatheter closure of atrial septal defects with 12-month follow-up data published[1]. The company focuses on innovative medical devices for interventional cardiology and other medtech applications.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Carag.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carag.

Explore the full profile